The
road
of
acceptance
oncologic
thermotherapy/hyperthermia
as
a
synergistic
modality
in
combination
with
standard
therapies
is
still
bumpy.
This
partially
due
to
the
lack
level
I
evidence
from
international,
multicentric,
randomized
clinical
trials
including
large
patient
numbers
and
long
term
follow-up.
Therefore
we
need
more
EVIDENCE
trials,
HARMONISATION
global
for
existing
technologies
common
language
understood
by
all
stakeholders
INNOVATION
fields
biology,
clinics
technology
move
forward.
main
focus
this
reprint.
In
reprintyou
find
carefully
selected
peer-reviewed
contributions
Africa,
America,
Asia,
Europe.
published
papers
leading
scientists
over
world
covering
broad
range
timely
research
topics
might
also
help
strengthen
thermotherapy
on
level.
International Journal of Nanomedicine,
Год журнала:
2023,
Номер
Volume 18, С. 5607 - 5623
Опубликована: Окт. 1, 2023
Abstract:
Due
to
their
non-toxic
function
in
biological
systems,
Iron
oxide
NPs
(IO-NPs)
are
very
attractive
biomedical
applications.
The
magnetic
properties
of
IO-NPs
enable
a
variety
We
evaluated
the
usage
for
anticancer
effects.
This
paper
lists
applications
general
and
clinical
targeting
IO-NPs.
application
IONPs
along
with
photothermal
therapy
(PTT),
photodynamic
(PDT),
hyperthermia
(MHT)
is
highlighted
this
review's
explanation
cancer
treatment
strategies.
study
shows
that
play
beneficial
role
activity
because
biocompatibility,
biodegradability,
simplicity
production,
hybrid
forms
In
review,
we
have
briefly
discussed
used
PTT,
PDT,
MHT.
particular
effect
on
when
combined
MHT
were
key
topics
review
covered
depth.
formulations
may
be
uniquely
specialized
treatments
MHT,
according
investigation.
Keywords:
cancer,
hyperthermia,
iron
oxide,
therapy,
near-infrared
International Journal of Hyperthermia,
Год журнала:
2022,
Номер
39(1), С. 1126 - 1140
Опубликована: Авг. 23, 2022
Biological
modeling
for
anti-cancer
treatments
using
mathematical
models
can
be
very
supportive
in
gaining
more
insight
into
dynamic
processes
responsible
cellular
response
to
treatment,
and
predicting,
evaluating
optimizing
therapeutic
effects
of
treatment.
This
review
presents
an
overview
the
current
status
biological
hyperthermia
combination
with
radiotherapy
(thermoradiotherapy).
Various
distinct
have
been
proposed
literature,
varying
complexity;
initially
aiming
model
effect
alone,
later
on
predict
combined
thermoradiotherapy
Most
commonly
used
are
based
extension
linear-quadratic
(LQ)-model
enabling
easy
translation
where
LQ
is
widely
used.
Basic
predictions
cell
survival
further
progressed
toward
3
D
equivalent
dose
predictions,
i.e.,
radiation
that
would
needed
without
achieve
same
as
approach,
use
temperature-dependent
parameters,
allows
theoretical
evaluation
effectiveness
different
treatment
strategies
individual
patients,
well
patient
cohorts.
discusses
significant
progress
has
made
radiotherapy.
In
future,
when
adequate
LQ-parameters
will
available
a
large
number
tumor
sites
normal
tissues,
expected
great
clinical
importance
optimize
treatments,
protocols
guide
studies.
Strahlentherapie und Onkologie,
Год журнала:
2024,
Номер
200(6), С. 512 - 522
Опубликована: Янв. 4, 2024
Abstract
Background
Hyperthermia
treatment
quality
is
usually
evaluated
by
thermal
(dose)
parameters,
though
hyperthermic
radiosensitization
effects
are
also
influenced
the
time
interval
between
two
modalities.
This
work
applies
biological
modelling
for
clinical
evaluation
of
cervical
cancer
patients
treated
with
radiotherapy
plus
hyperthermia
calculating
equivalent
radiation
dose
(EQD
RT
,
i.e.,
needed
same
effect
alone).
Subsequent
analyses
evaluate
impact
logistics.
Methods
Biological
was
performed
58
23–28
fractions
1.8–2
Gy
4–5
weekly
sessions.
Measured
temperatures
(T50)
and
recorded
intervals
sessions
were
used
to
calculate
EQD
using
an
extended
linear
quadratic
(LQ)
model
LQ
parameters
based
on
extensive
experimental
data.
Next,
a
30-min
(optimized
logistics)
as
well
4‑h
(suboptimal
evaluated.
Results
Median
average
measured
T50
41.2
°C
(range
39.7–42.5
°C)
79
min
34–125
min),
respectively,
resulting
in
median
total
enhancement
(D50)
5.5
(interquartile
range
[IQR]
4.0–6.6
Gy).
For
intervals,
would
increase
~30%
7.1
(IQR
5.5–8.1
Gy;
p
<
0.001).
In
case
~
40%
decrease
could
be
expected:
3.2
2.3–3.8
Normal
tissue
negligible
(<
0.3
Gy),
even
short
intervals.
Conclusion
useful
addition
standard
treatments.
Optimizing
logistics
shorten
seems
worthwhile
improve
efficacy.
International Journal of Hyperthermia,
Год журнала:
2024,
Номер
41(1)
Опубликована: Июль 17, 2024
There
is
an
ongoing
scientific
discussion,
that
anti-cancer
effects
induced
by
radiofrequency
(RF)-hyperthermia
might
not
be
solely
attributable
to
subsequent
temperature
elevations
at
the
tumor
site
but
also
non-temperature-induced
effects.
The
exact
molecular
mechanisms
behind
said
potential
non-thermal
RF
remain
largely
elusive,
however,
limiting
their
therapeutical
targetability.
Cancers,
Год журнала:
2023,
Номер
15(3), С. 742 - 742
Опубликована: Янв. 25, 2023
Purpose:
This
systematic
literature
review
summarizes
clinical
studies
and
trials
involving
combined
non-ablative
hyperthermia
re-irradiation
in
locoregionally
recurrent
cancer
except
breast
cancer.
Methods:
One
database
one
registry,
MEDLINE
clinicaltrials.gov,
respectively,
were
searched
for
on
non-breast
patients.
Extracted
study
characteristics
included
treatment
modalities
dose
concepts.
Outcomes
of
interest
tumor
response,
survival
measures,
toxicity
data
palliation.
Within-study
bias
assessment
the
identification
conflict
(COI).
The
final
search
was
performed
29
August
2022.
Results:
Twenty-three
articles
analysis,
reporting
603
patients
with
eight
major
types.
Twelve
(52%)
retrospective
studies.
Only
randomized
trial
identified.
No
COI
statement
declared
11
Four
remaining
twelve
exhibited
significant
COI.
Low
patient
numbers,
high
heterogeneity
endpoints,
as
well
within-
across-study
impeded
synthesis
results.
Conclusion:
Outside
cancer,
role
moderate
can
so
far
not
be
established.
underscores
necessity
more
to
generate
higher
levels
evidence
hyperthermia.
Cancers,
Год журнала:
2022,
Номер
14(19), С. 4795 - 4795
Опубликована: Сен. 30, 2022
The
challenge
to
explain
the
diffuse
and
unconclusive
message
reported
by
hyperthermia
studies
investigating
thermal
dose
parameter
is
still
be
unravelled.
In
present
review,
we
investigated
a
wide
range
of
technical
clinical
parameters
characterising
treatment
better
understand
improve
probability
detecting
effect
relationship
in
studies.
We
performed
systematic
literature
review
obtain
associations
temperature
with
outcome
or
acute
toxicity.
Different
characteristics
were
retrieved,
their
influence
on
was
assessed.
literature,
found
forty-eight
articles
relationships.
These
comprised
total
4107
patients
different
tumour
pathologies.
association
between
endpoint
90%
articles,
while
correlation
toxicity
50%
articles.
Significant
temperature-related
63%
studies,
those
15%
One
clear
difficulty
for
advancement
that
often
omitted
fundamental
information
regarding
treatment,
among
investigated,
thermometry
details
seldom
divergently
reported.
To
overcome
this,
propose
definition
terms
should
treatments.
A
consistent
report
data
will
allow
use
further
continue
quest
The
road
of
acceptance
oncologic
thermotherapy/hyperthermia
as
a
synergistic
modality
in
combination
with
standard
therapies
is
still
bumpy.
This
partially
due
to
the
lack
level
I
evidence
from
international,
multicentric,
randomized
clinical
trials
including
large
patient
numbers
and
long
term
follow-up.
Therefore
we
need
more
EVIDENCE
trials,
HARMONISATION
global
for
existing
technologies
common
language
understood
by
all
stakeholders
INNOVATION
fields
biology,
clinics
technology
move
forward.
main
focus
this
reprint.
In
reprintyou
find
carefully
selected
peer-reviewed
contributions
Africa,
America,
Asia,
Europe.
published
papers
leading
scientists
over
world
covering
broad
range
timely
research
topics
might
also
help
strengthen
thermotherapy
on
level.
